Drugs in Dev. Immunology
Phase II
United Kingdom 
Lead Product(s) : Alvelestat
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MPH966 (alvelestat) is an oral drug that is being researched in people with alpha-1 antitrypsin deficiency (AATD) lung disease. It acts to inhibit the neutrophil elastase enzyme and Mereo believes that it has the potential to protect AATD patients from f...
Product Name : MPH-966
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 21, 2023
Lead Product(s) : Alvelestat
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belimumab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Benlysta Granted Orphan Drug Designation by US FDA For the Potential Treatment of Systemic Sclerosis
Details : A fully human monoclonal antibody, Benlysta (belimumab) inhibits the prolonged survival of B cells induced by increased BLyS, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.
Product Name : Benlysta
Product Type : Antibody
Upfront Cash : Inapplicable
January 02, 2023
Lead Product(s) : Belimumab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alvelestat
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Alvelestat (MPH966) is an investigational oral neutrophil elastase inhibitor that is being researched in people with alpha-1 antitrypsin deficiency (AATD) lung disease.
Product Name : MPH-966
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 17, 2022
Lead Product(s) : Alvelestat
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Seven of nine patients responded to rVA576 (nomacopan) with three, regarded as complete responders, showing >80% reduction in BPDAI (BP disease activity index)activity and four patients showing >70% reduction in pruritis by day 42; two of nine patients w...
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
October 05, 2022
Lead Product(s) : Nomacopan
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IMP731
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Immutep
Deal Size : Inapplicable
Deal Type : Inapplicable
Immutep Announces that the Phase II Ulcerative Colitis Study of GSK2831781 Has Been Discontinued
Details : GSK, has stopped its Phase II trial of anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (derived from Immutep’s IMP731 antibody), in patients with active ulcerative colitis. The trial was stopped based on the assessment of clinical data of plan...
Product Name : GSK2831781
Product Type : Antibody
Upfront Cash : Inapplicable
January 22, 2021
Lead Product(s) : IMP731
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Immutep
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan,Prednisone
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Treatment arms will be tapered to minimal OCS and an important secondary endpoint is reduction in cumulative OCS on nomacopan as high dose OCS are regarded as unsafe in this vulnerable patient population.
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
December 08, 2020
Lead Product(s) : Nomacopan,Prednisone
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The poster presentation will describe the safety & efficacy data from Akari’s Phase II clinical trial of nomacopan in adult patients with mild-moderate bullous pemphigoid. The PhII data was the basis for the agreement of the FDA & EMA that Akari may pr...
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
October 27, 2020
Lead Product(s) : Nomacopan
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The positive opinion comes at the heels of successful completion of a Phase II study in BP where the combined therapeutic role of both complement (C5) and leukotriene (LTB4) has been well documented.
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
May 21, 2020
Lead Product(s) : Nomacopan
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The EMA and the FDA have both agreed to a Phase III randomized placebo-controlled study with nomacopan in moderate to severe bullous pemphigoid (BP) patients with a primary endpoint of disease remission on minimal oral corticosteroids (OCS).
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
January 10, 2020
Lead Product(s) : Nomacopan
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Akari Therapeutics achieved the primary and secondary endpoints for nomacopan in its Phase II trial in BP and is planning to discuss Phase III pivotal study designs with the FDA and EMA.
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
January 05, 2020
Lead Product(s) : Nomacopan
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
